Halozyme Therapeutics, Inc. (NASDAQ:HALO) Weekly Ratings as of May 17, 2018

May 17, 2018 - By Sergio Grout

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo
Big Money Sentiment increased to 1.66 in 2017 Q4. It has change of 0.40, from 2017Q3’s 1.26. The ratio is positive due to Halozyme Therapeutics, Inc. positioning: 13 sold and 45 reduced. 39 funds bought stakes and 57 increased stakes. Investors holded 118.53 million in 2017Q3 but now own 118.31 million shares or 0.18% less.
Price T Rowe Associate Md has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Sei Invests owns 309,057 shs for 0.02% of their capital. Senzar Asset Mgmt Ltd Llc has 537,500 shs for 2.78% of their capital. Morgan Stanley holds 575,381 shs. Thompson Davis has invested 0.02% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Schwab Charles Invest Management owns 661,013 shs. Manufacturers Life Ins Com The holds 0.02% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 716,482 shs. Fortaleza Asset Management Incorporated holds 7,941 shs. Horizon Kinetics Ltd reported 19,208 shs. Smith Asset Management Ltd Partnership, a Texas-based fund reported 26,980 shs. M&T National Bank & Trust reported 34,362 shs. Virtus Advisers invested in 19,208 shs or 0% of the stock. Ameriprise Fincl accumulated 107,051 shs or 0% of the stock. Doheny Asset Ca reported 107,800 shs or 1.02% of all its holdings. Brown Advisory Inc reported 0.01% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

A total of 6 analysts rate Halozyme (NASDAQ:HALO) as follows: 3 “Buy”, 2 “Hold” and 1 “Sell”. Тherefore 50% are bullish. (NASDAQ:HALO) has 9 ratings reports on May 17, 2018 according to StockzIntelligence. On Monday, May 14 the rating was maintained by Canaccord Genuity with “Buy”. On Wednesday, November 22 the rating was downgraded by Barclays Capital to “Hold”. On Wednesday, January 24 Deutsche Bank maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) with “Buy” rating. On Wednesday, February 21 Canaccord Genuity maintained the shares of HALO in report with “Buy” rating. On Friday, May 11 Barclays Capital downgraded Halozyme Therapeutics, Inc. (NASDAQ:HALO) to “Underweight” rating. On Wednesday, February 21 JP Morgan maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating. JP Morgan has “Overweight” rating and $22 target. The stock rating was maintained by BMO Capital Markets with “Market Perform” on Thursday, February 22. Listed here are Halozyme Therapeutics, Inc. (NASDAQ:HALO) PTs and latest ratings.

14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade
22/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $18 New Target: $19 Maintain
21/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $22 Maintain
24/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $21.0 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
17/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $18.0
22/11/2017 Broker: Barclays Capital Rating: Hold New Target: $19.0 Downgrade

The stock decreased 2.47% or $0.46 during the last trading session, touching $18.16.Currently Halozyme Therapeutics, Inc. is uptrending after 32.10% change in last May 17, 2017. HALO has also 644,666 shares volume. HALO outperformed by 20.55% the S&P 500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The firm is worth $2.60 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.The P/E ratio is 40.36. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were released by Benzinga.com, Benzinga.com and Seekingalpha.com. The first one has “22 Stocks Moving In Friday’s Pre-Market Session” as a title and was released on May 11, 2018. The next is “38 Stocks Moving In Friday’s Mid-Day Session” on May 11, 2018. And last was released on May 11, 2018, called “Premarket analyst action – healthcare”.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.